Rocket Pharmaceuticals (RCKT) AI Stock Analysis

• Market Cap: $471.19M
• Dividend Yield: N/A
• Average Volume (3M): 3.03M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.50
• Revenue Growth: N/A
• EPS Growth: 18.39%
• Country: US
• Employees: 299
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.38
• Shares Outstanding: 108,569,145
• 10 Day Avg. Volume: 3,527,586
• 30 Day Avg. Volume: 3,031,568
• PEG Ratio: 0.07
• Price to Book (P/B): 1.41
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.05
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -164.83
• Enterprise Value/Ebitda: -2.02
• 1Y Price Target: $9.00
• Price Target Upside: 117.39% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): -1.5
• Revenue Forecast (FY): $17.09M

• Rating: 49 Neutral
• Price Target: $4.00 ▼(-3.38% Downside)
• Action: Reiterated Date: 02/28/26
• Date: Action: Reiterated 02/28/26

The score is held back primarily by weak financial performance (no revenue, persistent losses, and ongoing cash burn with equity erosion risk). Technicals are supportive due to strong trend and positive MACD, but extremely overbought RSI/Stochastics temper the technical score. Valuation is constrained by negative earnings and no provided dividend yield.

Positive Factors

Targeted rare-disease gene therapy pipeline

A focused pipeline in gene therapies for rare diseases aligns Rocket with durable structural demand: high unmet medical need, potential for regulatory incentives, and concentrated clinical programs. This specialization can sustain long-term value creation if trials progress and approvals are achieved.

New at-the-market equity program

The $100M ATM establishes a flexible, ongoing capital source that reduces timing risk for funding clinical development. For a pre-commercial biotech with steady burn, structural access to equity markets supports ongoing trials and operations without adding debt, preserving optionality.

Relatively low financial leverage

Modest leverage lowers fixed financing costs and interest burden, improving resilience while the company consumes cash for R&D. Structurally low debt gives Rocket financial flexibility to pursue development or raise equity without heavy servicing constraints over the next several quarters.

Negative Factors

No product revenue

Lack of product revenue means Rocket cannot self-fund commercialization or offset R&D spending, making long-term sustainability dependent on successful trials or external financing. This structural revenue gap elevates dilution and execution risk over multiple funding cycles.

Persistent negative cash flow / high cash burn

Sustained negative operating and free cash flow (~$190M/year) creates an ongoing need for external capital. Over a multi-quarter horizon, this magnifies funding risk, can force dilutive equity raises or milestone-driven partnerships, and may delay development timelines if financing slows.

Equity erosion and negative returns

Material declines in equity and persistently negative ROE reflect capital depletion from operating losses. This weakens the balance-sheet cushion, increases creditor and investor sensitivity, and raises the probability of future dilution or constrained strategic choices if clinical outcomes don't improve.

Rocket Pharmaceuticals Business Overview & Revenue Model

Company Description

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.

How the Company Makes Money

Rocket Pharmaceuticals is a clinical-stage company; therefore, it does not primarily generate revenue from selling approved products. Its revenue, when present, generally comes from non-product sources such as collaboration or partnership arrangements (e.g., upfront payments, research funding reimbursements/cost-sharing, development and regulatory milestone payments, and sales-based milestones and/or royalties if partnered products are commercialized) and other operating income. The company’s ability to generate future revenue is principally tied to (1) advancing its gene therapy candidates through clinical trials, (2) obtaining regulatory approvals, and (3) either commercializing therapies itself (which would create product sales revenue) or monetizing programs through licensing/collaboration deals (which would create milestone and royalty income). If specific, current partnership terms or material counterparties are required, they are null.

Rocket Pharmaceuticals Financial Statement Overview

Summary

Financials reflect a pre-commercial biotech profile: essentially no revenue, large and persistent operating/net losses, and consistently negative operating and free cash flow. The balance sheet has modest leverage, but equity has fallen materially in recent years, and cash burn remains high, implying continued funding reliance.

Income Statement

Across the annual periods provided, the company reports essentially no revenue, while operating losses remain large and persistent (EBIT and net income are deeply negative each year). Losses improved in 2025 versus 2024 (net loss narrowed), but the longer trend still reflects heavy ongoing R&D/operating spend without an offsetting revenue base, keeping profitability weak and limiting visibility on near-term earnings power.

Balance Sheet

The balance sheet is supported by meaningful equity and relatively low leverage, with debt-to-equity staying modest (~0.05–0.09 in recent years, down from ~0.12 in 2020). However, equity has fallen materially from 2023–2025 (consistent with sustained losses), and returns on equity are sharply negative, highlighting ongoing capital erosion risk if losses persist.

Cash Flow

Cash generation is a key weakness: operating cash flow and free cash flow are consistently negative, and free cash flow declined further in 2025 versus 2024. While cash burn improved meaningfully versus 2020, the company is still consuming close to ~$190M of cash annually (2025), indicating continued reliance on external funding (equity or debt) until revenues scale.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-11.03M	0.00	0.00	0.00	0.00
EBITDA	-210.21M	-247.49M	-236.62M	-213.69M	-157.81M
Net Income	-223.12M	-258.75M	-245.59M	-221.86M	-169.07M
Balance Sheet
Total Assets	330.45M	527.70M	566.34M	551.81M	497.02M
Cash, Cash Equivalents and Short-Term Investments	188.93M	372.34M	373.18M	356.39M	388.74M
Total Debt	24.88M	25.50M	25.04M	22.87M	22.60M
Total Liabilities	53.23M	64.47M	73.77M	62.12M	42.30M
Stockholders Equity	277.22M	463.23M	492.57M	489.69M	454.72M
Cash Flow
Free Cash Flow	-190.45M	-215.59M	-211.39M	-186.76M	-128.88M
Operating Cash Flow	-190.01M	-209.72M	-194.92M	-178.14M	-121.16M
Investing Cash Flow	103.77M	131.71M	-98.07M	-69.33M	18.85M
Financing Cash Flow	148.00K	185.74M	208.40M	155.29M	37.68M

Rocket Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 4.14
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RCKT, the sentiment is Neutral. The current price of 4.14 is below the 20-day moving average (MA) of 4.66, above the 50-day MA of 3.98, and above the 200-day MA of 3.43, indicating a neutral trend. The MACD of 0.16 indicates Positive momentum. The RSI at 44.71 is Neutral, neither overbought nor oversold. The STOCH value of 14.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RCKT.

Rocket Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AUTL	51 Neutral	$372.60M	-1.37	-63.76%	―	407.86%	30.35%
RCKT	49 Neutral	$471.19M	-2.29	-65.76%	―	―	18.39%
FDMT	49 Neutral	$471.21M	-3.10	-47.27%	―	―	―
DRTS	49 Neutral	$633.67M	-9.36	-57.29%	―	―	-22.82%
CTMX	46 Neutral	$759.03M	-33.83	-19.77%	―	-10.26%	144.62%
ASMB	45 Neutral	$453.36M	-62.28	-59.01%	―	31.30%	32.79%

Rocket Pharmaceuticals Corporate Events

Rocket Pharmaceuticals Launches New $100M At-The-Market Program

On March 10, 2026, Rocket Pharmaceuticals, Inc. entered into a new at-the-market equity offering program with Cantor Fitzgerald & Co., allowing the company to sell up to $100 million of its common stock from time to time under a previously filed shelf registration. The arrangement gives Rocket flexibility to control the timing, size, pricing, and method of stock sales on Nasdaq or other markets, with Cantor acting on a commercially reasonable efforts basis and receiving up to a 3% commission plus expense reimbursement.

The company simultaneously terminated its prior at-the-market sales agreement with Cowen and Company, LLC, which had been in place since February 28, 2022 and amended on September 12, 2023. The shift to a new sales agent marks an adjustment in Rocket’s capital-raising strategy, potentially affecting its funding costs and access to equity markets while maintaining an established mechanism for incremental share issuance.

The most recent analyst rating on (RCKT) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Rocket Pharmaceuticals stock, see the RCKT Stock Forecast page.